Pathological alpha-synuclein seeds mark synucleinopathy biology
PrimaryAmprion's core theory is that misfolded, pathological alpha-synuclein in cerebrospinal fluid is a causal-pathology-aligned biomarker for synucleinopathies such as Parkinson's disease, Lewy body dementia, and related neurodegenerative disease. A seed amplification assay should detect the self-propagating alpha-synuclein species underlying disease biology, giving clinicians and researchers biological classification beyond symptoms. Testable predictions are that CSF alpha-synuclein SAA positivity should be enriched in clinically defined synucleinopathies, remain stable within individuals over time, and support earlier or more precise classification of age-related neurodegenerative disease.
Popperian evaluation
The premise is strong: pathological alpha-synuclein seeds in CSF track the biology of several synucleinopathies, and the longitudinal data make random assay noise a poor explanation. The weak point is causal wording. The assay can detect seeding biology, but detection alone does not prove that the measured CSF species drives disease in each patient.
Supporting evidence: CSF SAA separated Lewy body diseases from multiple system atrophy, with type 1 seeding in most Parkinson's disease and pure autonomic failure patients and type 2 seeding in most multiple system atrophy patients.; In PPMI, 96% of SAA-positive Parkinson's disease participants stayed positive, and 92% of SAA-negative Parkinson's disease participants stayed negative across serial CSF samples.; In the BEAT-PD genetic-risk cohort, 44 of 45 participants with follow-up kept their baseline SAA status at year 2.
Counter evidence: LRRK2 Parkinson's disease carriers had lower SAA positivity than idiopathic Parkinson's disease and GBA1 Parkinson's disease, so a clinical Parkinson's label does not always mean detectable CSF alpha-synuclein seeding.; Different assay conditions produced different diagnostic profiles, which means the biological readout depends on assay context.
The theory explains a lot of the pattern: enrichment in synucleinopathies, subtype separation, and stable individual status. It also explains why symptom-based groups split biologically, especially in LRRK2 Parkinson's disease. The fit is incomplete because mixed neurodegenerative disease and assay-condition effects leave room for alternative explanations, including different seed conformations, sampling effects, or disease biology outside detectable CSF alpha-synuclein.
Supporting evidence: SAA positivity was enriched in clinically defined synucleinopathies and showed disease-profile differences across Parkinson's disease, dementia with Lewy bodies, controls, and multiple system atrophy.; At-risk SAA-positive participants had higher prodromal Parkinson's disease probability scores.; Faster CSF alpha-synuclein SAA reaction times predicted the diffuse malignant subtype of Parkinson's disease at 10-year follow-up.
Counter evidence: SAA positivity in Alzheimer's disease was associated with higher plasma neurofilament light chain, which may point to mixed pathology or broader neurodegeneration rather than clean synucleinopathy classification.; LRRK2 Parkinson's disease can be clinically similar while often lacking detectable SAA positivity.
This is highly testable. The theory makes concrete predictions about who should test positive, whether status should persist, and whether the assay should improve biological classification. It would take real damage if longitudinal cohorts showed frequent positive-to-negative switching, if controls and synucleinopathy cases had similar positivity rates, or if assay positivity failed to predict pathology at autopsy.
Supporting evidence: The theory predicts enrichment of CSF alpha-synuclein SAA positivity in Parkinson's disease, Lewy body dementia, pure autonomic failure, and multiple system atrophy.; The theory predicts within-person stability, and PPMI reported high status consistency over a median 2.0 years, with follow-up spanning 0.4 to 11.4 years.; The theory predicts earlier or more precise classification, tested through prodromal probability scores and 10-year subtype prediction.
Counter evidence: Some claims remain softer than others: 'causal-pathology-aligned' is harder to falsify than assay positivity, stability, or subtype prediction.; Assay-condition dependence can blur falsification unless protocols and disease contexts are specified in advance.
Reasoning tree
Public endorsements
The publication record supports the theory directly. The 2024 NSD-ISS paper argues that pathological alpha-synuclein detected in CSF by seed amplification assay should anchor a biological definition of Parkinson's disease and related synuclein disorders. The 2025 prodromal PD paper reports that CSF alpha-synuclein SAA positivity is linked to higher phenoconversion risk and that longitudinal assays in 48 prodromal cases did not change, which fits the theory's stability claim. The MSA and iNPH papers also treat CSF alpha-synuclein seeding activity as a disease-relevant marker that can classify underlying synuclein pathology beyond symptoms.
Evidence publication IDs: d4efc229-fc9c-4cfb-9963-741fa944ce12, c5a822c0-fddb-4e0a-a283-d48eafa5b714, 27a082b1-f977-4b98-b913-7a2a93d3ff99, 9f2e8c2b-95b5-4485-a8b9-d9dfff4cfa5f
Soto does more than mention the idea. As Amprion co-founder and CSO, he is tied directly to the company’s seed-amplification platform, and he has publicly argued that symptom-based Parkinson’s diagnosis catches patients when disease is already advanced. The record also says he developed key IP around Amprion’s PMCA technology, and MJFF credited his work on misfolded alpha-synuclein and diagnostic tests for Parkinson’s. That is a public endorsement of the core theory that pathological alpha-synuclein seeds track disease biology and can support earlier classification.
Evidence publication IDs: df52b58c-4585-4e5a-a7d8-4b8b16a1e488, 1b6b5f39-7b30-4182-83c2-4b9b27b5e1e2
Karen MacLeod is a listed coauthor on the 2022 PubMed paper "Aggregation-Seeding Forms of α-Synuclein Are Not Detected in Acute Coronavirus Disease 2019 Cerebrospinal Fluid," with Amprion affiliation. That is a public, relevant mention of alpha-synuclein seed detection, but this record does not directly argue that CSF alpha-synuclein seeds mark synucleinopathy biology in Parkinson's disease or Lewy body dementia.
Evidence publication IDs: 30316b95-4d9b-465e-8462-2d102ab55e6e